Published online before print January 17, 2005, doi: 10.1161/01.CIR.0000153272.48711.B9
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;111:343-348.)
© 2005 American Heart Association, Inc.
Molecular Cardiology |
Irbesartan and Lipoic Acid Improve Endothelial Function and Reduce Markers of Inflammation in the Metabolic Syndrome
Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) Study
From the Division of Cardiology, Emory University School of Medicine, Atlanta, Ga.
Correspondence to Bobby Khan, MD, PhD, Emory Division of Cardiology, 69 Jesse Hill Jr Dr, Suite C233, Atlanta, GA 30303. E-mail bkhan{at}emory.edu
Received August 16, 2004; revision received September 30, 2004; accepted October 13, 2004.
Background— The metabolic syndrome is associated with increased angiotensin II activity, induction of a proinflammatory and oxidative state, and endothelial dysfunction. We evaluated the ability of irbesartan, an angiotensin receptor blocker, and lipoic acid, an antioxidant, to affect endothelial function and inflammation in patients with the metabolic syndrome.
Methods and Results— We randomized 58 subjects with the metabolic syndrome in a double-blinded manner to irbesartan 150 mg/d (n=14), lipoic acid 300 mg/d (n=15), both irbesartan and lipoic acid (n=15), or matching placebo (n=14) for 4 weeks. Endothelium-dependent and -independent flow-mediated vasodilation was determined under standard conditions. Plasma levels of interleukin-6, plasminogen activator-1, and 8-isoprostane were measured. After 4 weeks of therapy, endothelium-dependent flow-mediated vasodilation of the brachial artery was increased by 67%, 44%, and 75% in the irbesartan, lipoic acid, and irbesartan plus lipoic acid groups, respectively, compared with the placebo group. Treatment with irbesartan and/or lipoic acid was associated with statistically significant reductions in plasma levels of interleukin-6 and plasminogen activator-1. In addition, treatment with irbesartan or irbesartan plus lipoic acid decreased 8-isoprostane levels. No significant changes in blood pressure were noted in any of the study groups.
Conclusions— Administration of irbesartan and/or lipoic acid to patients with the metabolic syndrome improves endothelial function and reduces proinflammatory markers, factors that are implicated in the pathogenesis of atherosclerosis.
Key Words: metabolic syndrome • endothelium • inflammation • angiotensin
This article has been cited by other articles:
 |
|
 |
|
  W.-J. Zhang, K. E. Bird, T. S. McMillen, R. C. LeBoeuf, T. M. Hagen, and B. Frei Dietary {alpha}-Lipoic Acid Supplementation Inhibits Atherosclerotic Lesion Development in Apolipoprotein E Deficient and Apolipoprotein E/Low-Density Lipoprotein Receptor Deficient Mice Circulation, January 22, 2008; 117(3): 421 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. VIRMANI, Z. K. BINIENDA, S. F. ALI, and F. GAETANI Metabolic Syndrome in Drug Abuse Ann. N.Y. Acad. Sci., December 1, 2007; 1122(1): 50 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ishida, T. Ohara, Y. Okuno, T. Ito, Y. Hirota, K. Furukawa, K. Sakaguchi, W. Ogawa, and M. Kasuga {alpha}-Lipoic Acid and Insulin Autoimmune Syndrome Diabetes Care, September 1, 2007; 30(9): 2240 - 2241. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gilliam-Davis, V. S. Payne, S. O. Kasper, E. N. Tommasi, M. E. Robbins, and D. I. Diz Long-term AT1 receptor blockade improves metabolic function and provides renoprotection in Fischer-344 rats Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1327 - H1333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-J. Zhang, H. Wei, T. Hagen, and B. Frei {alpha}-Lipoic acid attenuates LPS-induced inflammatory responses by activating the phosphoinositide 3-kinase/Akt signaling pathway PNAS, March 6, 2007; 104(10): 4077 - 4082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Luther, J. V. Gainer, L. J. Murphey, C. Yu, D. E. Vaughan, J. D. Morrow, and N. J. Brown Angiotensin II Induces Interleukin-6 in Humans Through a Mineralocorticoid Receptor-Dependent Mechanism Hypertension, December 1, 2006; 48(6): 1050 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ziegler, A. Ametov, A. Barinov, P. J. Dyck, I. Gurieva, P. A. Low, U. Munzel, N. Yakhno, I. Raz, M. Novosadova, et al. Oral Treatment With {alpha}-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy: The SYDNEY 2 trial. Diabetes Care, November 1, 2006; 29(11): 2365 - 2370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Miyata and C. van Ypersele de Strihou Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering Nephrol. Dial. Transplant., April 1, 2006; 21(4): 846 - 849. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Samudio, M. Konopleva, H. Pelicano, P. Huang, O. Frolova, W. Bornmann, Y. Ying, R. Evans, R. Contractor, and M. Andreeff A Novel Mechanism of Action of Methyl-2-cyano-3,12 Dioxoolean-1,9 Diene-28-oate: Direct Permeabilization of the Inner Mitochondrial Membrane to Inhibit Electron Transport and Induce Apoptosis Mol. Pharmacol., April 1, 2006; 69(4): 1182 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zuccollo, C. Shi, R. Mastroianni, K. A. Maitland-Toolan, R. M. Weisbrod, M. Zang, S. Xu, B. Jiang, J. M. Oliver-Krasinski, A. J. Cayatte, et al. The Thromboxane A2 Receptor Antagonist S18886 Prevents Enhanced Atherogenesis Caused by Diabetes Mellitus Circulation, November 8, 2005; 112(19): 3001 - 3008. [Abstract] [Full Text] [PDF]
|
|